Note to the businessman

Found results: 345

Note to the businessman

Cancer gene therapy and pharmacoeconomics

The introduction of cancer gene therapy will cause serious financial consequences for the health systems of even rich countries.

11.01.2018
Note to the businessman

Novelties of biomedicine

The most interesting and important of the world events in the field of drug development and healthcare for the 2nd half of 2017

26.12.2017
Note to the businessman

Six million for OncoTartis

The funds will be used to conduct phase I clinical trials of the drug OT-82 for the treatment of resistant forms of acute leukemia.

12.12.2017
Note to the businessman

Investing in diabetes treatment

An American startup hoping to cure type one diabetes with an implant with insulin-producing cells has raised $114 million.

30.11.2017
Note to the businessman

Catch up? Overtake???

It is not entirely clear how the development of domestic sequencers looks from a technical and economic point of view...

13.11.2017
Note to the businessman

Longevity Industry

The review is addressed to investment firms and large companies interested in medical methods to combat aging.

24.10.2017
Note to the businessman

Live money

This year, new records are expected to be set in terms of investments in the fields of life sciences and digital medicine.

13.10.2017
Note to the businessman

Playing by the new rules

PharmaTimes portal discussed the future of artificial intelligence technologies in pharmaceuticals with AI expert Jackie Hunter.

22.09.2017
Note to the businessman

How to beat old age

Ilya Popov, member of the industry working groups under the Ministry of Finance of the Russian Federation, the Chamber of Commerce and Industry of the Russian Federation and Business Russia - on the prospects for the development of the biomedical technologies market.

01.09.2017
Note to the businessman

The prospects of epigenetics are questionable

Roche did not want to license its leading candidate drug for the treatment of acute myeloid leukemia and solid tumors from the Spanish Orizn Ginomix.

24.07.2017
Note to the businessman

Startup for startup's sake

Nikolay Dobrovolsky, Vice President of Parallels: venture business is like a lottery. Few are lucky. How not to discover that you are developing a startup for the sake of a startup?

14.06.2017
Note to the businessman

The $140 billion market

Currently, targeted drug delivery is developing especially rapidly from all areas of nanomedicine, and large amounts of funding will be allocated for this.

22.05.2017
Note to the businessman

Venture Market Navigator 2016

PricewaterhouseCoopers and the Russian Venture Company present the sixth annual review of the Russian venture industry "MoneyTreeTM: Navigator of the Venture Market" for 2016.

28.03.2017
Note to the businessman

Indicators of innovation activity

Business innovation activity in Russia continued to decline in 2015: innovation costs in all industries, except telecom and IT, decreased by 10.5% in 1995 prices.

16.03.2017
Note to the businessman

Koshcheev 's secrets

Unlike gerontology, antiaging (prevention of aging) offers services, for example, xenotherapy and detox droppers, mainly to patients aged 35-55 years.

01.03.2017
Note to the businessman

Are Biotech expecting a takeover?

Biotech companies have begun to feel insecure to such an extent that many analysts predict that in 2017 this industry will be overwhelmed by a wave of acquisitions.

24.01.2017